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Introduction
Differentiation syndrome (DS), formerly known as retinoic acid syndrome, can be a lifethreatening complication in patients with acute promyelocytic leukemia (APL) undergoing induction therapy with all-trans retinoic acid (ATRA) or arsenic trioxide. The full-blown syndrome is characterized by unexplained fever, weight gain, peripheral edema, dyspnea with interstitial pulmonary infiltrates, pleuropericardial effusion, hypotension, and acute renal failure. 1 The reported incidence of this syndrome of uncertain pathogenesis ranges from 2% to 27%. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] This wide range is probably because of the different criteria used for the diagnosis of DS, and to the effects on the incidence and severity of the syndrome due to differences in induction therapy and supportive measures. In this regard, the early addition of chemotherapy to ATRA and the administration of high-dose dexamethasone at the onset of the first symptoms appear to have reduced the DS-related mortality to 1% or less in the most recent trials. [9] [10] [11] Although the mortality associated with DS is now relatively low, the development of this complication has additional implications, such as an increase in morbidity leading to an increased use of hospital resources, and has been suggested that this is associated with an increased risk of relapse independent of the white blood cell (WBC) count. 11 However, this interesting finding reported by the European APL Group has not yet been confirmed in other studies.
Apart from a peak WBC count frequently observed at the onset of DS symptoms, 2 very little is known about other factors predictive for DS when patients are treated with ATRA combined with chemotherapy. In this context, the only published study including a significant number of patients found no prognostic factor, including pretreatment WBC count, associated to the development of DS. 10 Furthermore, the PETHEMA group has recently analyzed the causes and prognostic factors of induction failure, including death due to DS, but the incidence, time of occurrence, and prognostic factors of the development of this syndrome were not analyzed. 12 For personal use only. on . by guest www.bloodjournal. org From This study aims to analyze the incidence, clinical manifestations and prognostic factors associated with DS, as well as the short-and long-term outcomes for patients developing this syndrome, in a large series of newly diagnosed APL patients treated with ATRA and idarubicin (AIDA regimen) who were enrolled in two consecutive studies by the PETHEMA Group (LPA96 and LPA99). The impact of the different corticosteroid prophylaxis used in these trials on the development and severity of DS was also analyzed.
Materials and methods

Eligibility
For enrolment in the consecutive PETHEMA LPA96 and LPA99 trials, patients were 
Induction therapy
Treatment with ATRA was started as soon as a diagnosis of APL by morphological criteria was made. 13, 14 
Management of DS and other supportive measures
Management of DS. Treatment with intravenous dexamethasone at a dose of 10 mg twice daily was started promptly at the very earliest symptom or sign of DS. ATRA was discontinued in cases where there was progression of the clinical symptoms of DS. In the LPA96 trial, patients with a WBC count > 5 × 10 9 /L (before or during treatment with ATRA) received prophylaxis with dexamethasone (10 mg/12h intravenously for 7 days), while in the LPA99 study all patients, regardless of WBC count, received DS prophylaxis with prednisone (0.5 mg/kg/d orally) from days 1 to 15. Diuretics were usually given to treat acute renal failure and weight gain, and dialysis or venous continuous ultrafiltration was given at physician discretion. Mechanical ventilation was indicated in some patients with severe acute respiratory failure.
Details about the management of coagulopathy, transfusion policy and other supportive measures have been described elsewhere.
12
Study definitions and endpoints
The remission induction response was assessed according to the criteria recently revised by Cheson et al. 17 A morphologic complete remission (CR) designation requires a patient to have less than 5% blasts and atypical promyelocytes in an
For personal use only. on June 10, 2017. by guest www.bloodjournal.org From aspirate sample, an absolute neutrophil count of > 1 × 10 9 /L and platelets of > 100 × 10 9 /L. The treatment failure group included those patients for whom treatment had failed to achieve a CR. The primary endpoint of the study was the assessment of the incidence of DS. Diagnosis of this syndrome was made according to the presence of the following symptoms and signs described by Frankel were not considered as DS. Death was attributed to DS when death occurred in patients with severe DS and was not explained by infection, hemorrhage, or other causes. DS was defined as "early" when it occurred within 7 days of the start of ATRA, or "late" when occurring more than 7 days after the start of ATRA.
Data collection and prognostic factors
Data were collected and registered prospectively. Thirty-six patient and disease characteristics documented at the initial evaluation were examined for the prognostic factor analysis to establish their relationship to the development of DS. Basic demographic data and clinical characteristics at presentation included age, gender, ECOG score, fever, and total body surface as well as liver and spleen enlargement. The following surface antigen markers were evaluated by multiparametric flow inmunocytometry: CD2, CD7, CD11b, CD13, CD14, CD15, CD19, CD34, CD56, and CD117. Positivity for a specific antigen was defined as expression of the corresponding surface marker by more than 20% of blast cells. Other variables such as PETHEMA LPA trial (LPA96 vs. LPA99), fibrinogen level, and the presence of coagulopathy were also included. Coagulopathy was defined as a prolonged prothrombin time and/or activated partial thromboplastin time in addition to hypofibrinogenemia and/or increased levels of fibrin degradation products or D-dimers.
The prognostic impact of DS on induction mortality and risk of relapse was also analyzed.
Statistical methods
Chi-square with Yates' correction, when appropriate, was used to analyze differences in the distribution of variables among patient subsets. Student's t-test and MannWhitney U test were used to compare continuous variables with normal and nonnormal distribution, respectively. P values were calculated using the two-tailed test.
Characteristics selected for inclusion in the multivariate analysis were those for which there was some indication of a significant association with DS in univariate analysis (P < 0.1) and, if available, those for which prior studies had suggested a possible relationship. Multivariate analysis was performed using a logistic regression model. 18 Missing data were substituted by the mean values from patients for whom data were available. 19 For univariate comparison, unadjusted time-to-event analyses (relapse-free survival (RFS)) were performed using the Kaplan-Meier estimate, 20 as well as log-rank tests and their generalizations. 12 LPA96 and LPA99 patients were comparable for all the baseline characteristics except for gender and serum albumin levels (female gender and low albumin levels more frequent in LPA99 trial, both P = 0.01).
Incidence and characteristics of patients with DS
Overall, 183 of 739 patients (24.8%) experienced DS, of whom 93 (12.6%) were classified as severe and 90 (12.2%) moderate DS. In 33 patients (4.5%) with possible DS, an unambiguous diagnosis of DS could not be made. This was due to the presence of concurrent medical problems that could explain the clinical manifestations.
These problems were pulmonary hemorrhage in 13 patients, pneumonia in eight, congestive cardiac failure in six, renal failure in three, and septic shock in three. Table 1 shows that age, serum creatinine levels, and WBC counts were higher among patients who developed DS compared with those who did not (P = 0.04, P = 0.03, and P = 0.0003, respectively). Patients with DS presented more frequently with coagulopathy (P = 0.02).
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Clinical manifestations and timing of DS
The most frequent clinical manifestations of severe DS were dyspnea (95%), pulmonary infiltrates (81%), unexplained fever (74%), weight gain > 5 kg (68%), pleural effusion (58%), and renal failure (46%). The frequencies of these symptoms were considerably less in moderate DS ( Table 2 ). As shown in Table 2 , there was a significantly higher frequency of hypotension in late severe DS compared with early severe DS (P = 0.007), whereas the frequency of other symptoms and signs did not differ statistically.
DS occurred at a median of 12 days after starting ATRA treatment (range 0 to 46 days). Severe DS occurred comparatively early, i.e. at a median of 6 days, while moderate DS appeared after a median interval of 15 days. A bimodal time distribution of the peak incidence of DS was observed ( Figure 1 ). The bimodal peak of incidence was observed in both moderate and severe DS. The first peak occurred during the first week of ATRA treatment in 47% of patients, and the second peak of new cases of DS was seen in the third week (25% of patients). During the second week only 5% of new cases of DS were noted. DS continued to develop in some patients in the fourth week (19%) and after day 29 (3%).
Outcomes of DS
A total of 667 of the 739 evaluable patients achieved morphologic CR (90.3%; 95% CI, 88.0%-92.4%). Of the 72 induction failures, 66 patients died during induction and the remaining six patients were registered by their physicians as resistant leukemia. These six patients were prematurely assessed as refractory to induction treatment (on days 18 to 33 post chemotherapy) according to the classical morphologic criteria for AML. In the six patients DS had been noted, i.e. late DS (onset on days 12, 13, 15, and 15), and early DS (in 2 patients on day 5).
The development of moderate DS had no impact on the death rate during induction (6% vs 7%, P = 0.82), but severe DS was associated with a higher induction death rate (26% vs 7%, P < 0.001). The induction mortality was 40% in patients with early severe For personal use only. on June 10, 2017. by guest www.bloodjournal.org From DS ( Table 3 ). The DS-associated mortality rate was 11% in patients with severe DS, while no cases of death resulting from DS were observed in patients with moderate DS.
Ten deaths related to DS occurring during induction have been described in detail elsewhere. 12 Hemorrhage-associated mortality was also higher in patients who developed severe DS as compared with patients with moderate DS or no DS (11% vs.
6% vs. 4%, respectively, P= .02).
Intravenous dexamethasone was administered in 90% of patients with severe DS and 82% of patients with moderate DS (Table 3) . ATRA was temporarily discontinued in 64% of patients with severe DS and 60% of patients with moderate DS. Diuretics, dialysis, and mechanical ventilation were more frequently used in patients with severe DS than in patients with moderate DS. Patients with severe DS required more plasma, platelets, and red blood cell transfusions during induction. Table 3 shows that severe DS was significantly associated with greater frequencies of thrombosis and grade 3-4 hepatotoxicity during induction, as compared to all other cases (P = 0.008 and P = 0.01, respectively). Time to neutrophil recovery was significantly shorter in patients with severe DS (P = 0.004). Patients with severe DS, especially those with late DS, spent more days in the hospital during induction treatment (P = 0.06).
Prognostic factors for DS
Factors predicting moderate DS. The univariate analysis of prognostic factors identified the following characteristics as significantly associated with moderate DS: high WBC count at presentation, with 10 × 10 9 /L as the most significant cutoff point; LDH greater than the upper laboratory normal (ULN) values; and PB blasts > 70% (Table 4) .
Multivariate analysis identified a WBC count greater than 10 × 10 9 /L as an independent prognostic factor for moderate DS (P = 0.039) ( Table 5 ).
Factors predicting severe DS. Univariate analysis identified the following prognostic factors as regards severe DS: high WBC count at presentation, with 5 × 10 9 /L as the For personal use only. on June 10, 2017. by guest www.bloodjournal.org From most significant cutoff point; abnormal levels of serum creatinine; FLT3-ITD mutations; microgranular subtype; short PML-RARA isoform; and male gender (Table 4) .
Following multivariate analysis, abnormal levels of serum creatinine (P = 0.004), WBC count > 5 × 10 9 /L (P = 0.021), and LPA96 protocol (P = 0.044) remained as independent prognostic factors for severe DS (Table 5 ).
Risk of relapse of patients developing DS
The overall seven-year RFS in patients with and without DS was 85% and 87%, respectively (P = 0.31) (Figure 2A ). Patients developing severe DS showed a significantly lower seven-year RFS in the LPA96 trial (60% vs 85%, P = 0.003) ( Figure   2B ). This difference was not apparent for patients treated on the LPA99 trial (86% vs 88%, P = 0.54) ( Figure 2C ). None of the 10 patients who had central nervous system relapse had previously experienced DS.
For
Discussion
This study shows that roughly one quarter of patients with APL undergoing induction therapy with the AIDA regimen develop DS, with an equal distribution between the moderate and severe forms of DS. Patients with moderate DS showed the same treatment outcome as regards induction death and relapse probability. Severe DS was associated with increased mortality during induction. A bimodal peak of incidence in the first and third week of ATRA treatment was observed for both moderate and severe DS. A lower overall incidence of severe DS was observed in patients enrolled in the idarubicin for consolidation, which may have contributed to the reduced relapse rate.
The variation in the incidence of DS associated with induction therapy in APL that has been previously reported is quite wide with a range from 2% to 27%. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The impact of DS on the treatment outcomes as reported has also been variable.
Differences of the effects of DS between studies could be a result of several factors.
The most likely explanation for different results relates to the lack of consensus in the definition, grading, and classification of the syndrome. Furthermore, the use of chemotherapy concurrent with ATRA in some but not in other studies has probably determined differences as regards the incidence and severity of DS. In this respect, the results of a randomized study that focused on patients with low WBC counts (< 5 × 11 and several nonrandomized studies 9, 23, 24 strongly suggest that the concurrent use of ATRA and chemotherapy decreases the incidence of DS. The GIMEMA group 9 using the AIDA regimen had reported a low incidence of DS of 2.5% (6 of 240 patients) but their definition of DS was notably different. They established a diagnosis of severe DS according the presence of 5 of the 7 signs and symptoms as originally described by Frankel et al. 1 As a matter of fact, when we apply the same definition to our series of 739 patients of the study reported herein, we estimate a similar incidence of 2.6%. In other published studies of concurrent ATRA/chemotherapy regimens, greater incidences of DS have been reported (11% to 16%), but often the diagnostic criteria for the syndrome had not been specifically defined 23, 24 or the diagnostic criteria had been less strict (three of seven signs and symptoms). 10 In the present study, we first assessed the most discriminating cutoff value for predicting outcomes. We then classified the DS as moderate or severe according to the presence of two to three, or more than three of the seven signs, respectively. This distinction allowed for the assessment of the different prognostic significance of severe DS. The development of severe but not moderate DS appeared to be associated with an increased death rate.
Interestingly, apart from a proportion of patients who died in the context of severe DS with apparently no other contributing cause of death, this complication was also associated with death resulting from hemorrhage. In line with this finding, a Japanese group 25 reported that patients with DS were more prone to develop severe hemorrhage during induction. In the present study, we found that severe DS, especially early DS, was associated with coagulopathy and a higher use of plasma, platelet, and red blood cell transfusions during induction. The exacerbation of the procoagulant state of APL that can be observed with the development of DS 26-29 may lead not only to an increased risk of hemorrhage but also to a higher incidence of thrombosis. This association of DS and activated procoagulation is also evident in the present study. On the other hand, as far as we know, a shorter period of neutropenia has not previously been reported, while the association of severe DS with an increased rate of grade 3-4 hepatotoxicity has also been noted in the early study by Frankel et al. 1 The
For personal use only. on June 10, 2017. by guest www.bloodjournal.org From phenomenon of the bimodal peak of incidence observed in the first and third week of ATRA treatment in both moderate and severe DS that our analysis reveals is remarkable. It should be noted that cases of early severe DS more frequently required mechanical ventilation and were associated with higher induction death rate than those occurring during the third week or beyond. In addition, early severe DS was characterized by a higher frequency of pulmonary infiltrates and weight gain, probably related to an initial rise of leukocytosis and fluid overload. In contrast, hypotension, unexplained fever, pericardial effusion, and renal failure were more frequent in late severe DS. We should emphasize that in this situation a differential diagnosis of DS from other clinical complications, particularly sepsis, may be difficult. Therefore, in these cases treatment of DS should be complemented with therapeutic measures addressing alternative possibilities that could also explain the symptoms. The European APL Group has reported an increased relapse rate in patients developing DS. 10, 11 We have confirmed this finding in patients developing severe DS
trial, however, patients with intermediate and high risk of relapse received ATRA and a reinforced dose of idarubicin for consolidation, which may have contributed to the reduced relapse rate. Finally, we found no association between DS and central nervous system relapse, as suggested by others. 10, 34 In conclusion, DS is a relatively frequent and serious complication in patients with APL undergoing induction with ATRA plus chemotherapy. Prophylaxis with prednisone has no impact on reducing mortality resulting from DS, but it is likely to reduce the incidence of severe DS. Although the question of whether the use of corticosteroid prophylaxis is advantageous should be definitively settled in randomized studies, this strategy can be considered in patients treated with ATRA plus chemotherapy, particularly taking into account that infectious mortality was not apparently increased when prednisone prophylaxis was systematically used. 12 Due to the association of severe DS with an increase of morbidity and mortality during induction, risk-adapted strategies focused on patients with adverse risk factors (WBC counts > 5 × 10 9 /L; abnormal levels of serum creatinine) deserve further research.
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